Adult Glioblastoma Clinical Trial
Official title:
Phase I Trial of R115777 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
This phase I trial studies the side effects and best dose of tipifarnib when given together with radiation therapy and temozolomide in treating patients with newly diagnosed glioblastoma multiforme. Tipifarnib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving tipifarnib together with radiation therapy and temozolomide may be a better way to treat glioblastoma multiforme.
PRIMARY OBJECTIVES:
I. Establish maximum tolerated dose (MTD) for tipifarnib (R115777) in combination with
temozolomide with radiation in patients not on enzyme-inducing anti-epileptic drugs
(EIAEDs).
II. To define the safety of R115777 in combination with temozolomide with radiation in this
patient population.
III. To assess for evidence of antitumor activity in this patient population.
OUTLINE: This is a dose-escalation study of tipifarnib.
TIPIFARNIB: Patients receive tipifarnib orally (PO) twice daily (BID) on days 1-21. Courses
repeat every 28 days in the absence of disease progression or unacceptable toxicity.
CONCURRENT CHEMOTHERAPY DURING RADIATION THERAPY: Within 5-9 days after starting tipifarnib,
patients undergo external beam radiation therapy (EBRT) daily and receive temozolomide PO
daily for 6 weeks.
POST-RADIATION CHEMOTHERAPY: Beginning at week 10 post-radiation therapy, patients receive
temozolomide PO on days 1-5. Treatment repeats every 28 days for 1 year or 12 complete
courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 4 months.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02530502 -
Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma
|
Phase 1 | |
Withdrawn |
NCT02194452 -
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
|
N/A | |
Completed |
NCT00238303 -
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00049387 -
Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
|
Phase 1 | |
Completed |
NCT02015819 -
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
|
Phase 1 | |
Active, not recruiting |
NCT02179086 -
Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
|
Phase 2 | |
Recruiting |
NCT04573140 -
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
|
Phase 1 | |
Active, not recruiting |
NCT00823797 -
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
|
Phase 2 | |
Completed |
NCT00045565 -
Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
|
Phase 1 | |
Completed |
NCT01977677 -
Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
|
Phase 1/Phase 2 | |
Completed |
NCT01648348 -
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
Completed |
NCT00004262 -
Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme
|
Phase 1 | |
Terminated |
NCT01575275 -
Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT01996527 -
3T MRI Biomarkers of Glioma Treatment Response
|
Early Phase 1 | |
Completed |
NCT01131234 -
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01119599 -
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
|
Phase 1 | |
Terminated |
NCT01103375 -
Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
|
Phase 1 | |
Completed |
NCT00459381 -
Pazopanib in Treating Patients With Recurrent Glioblastoma
|
Phase 2 | |
Completed |
NCT00316849 -
Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00016328 -
CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 2 |